Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
$ 1.48
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very low or no dividends
Data is available to registered users only
Data is available to registered users only
About
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are...
Company Valuation
Considering past and projected metrics, the stock is slightly 'cheaper' than its peers.
Data is available to registered users only
Target Price
The average target price of LVTX is 1.5 and suggests 1% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to decre
Data is available to registered users only
